Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma Trial
(MedPage Today) -- Progression-free survival (PFS) in unresectable melanoma improved significantly with the addition of an investigational histone deacetylase (HDAC) inhibitor to immunotherapy, a randomized trial showed. Median PFS increased from...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.